Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
Full history for every metric is available with a Kvantra account
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGD m | - | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | SGD m | -5 | -3 | ||||||
| Net profit | SGD m | - | -1 | -1 | -1 | -2 | -5 | -3 | - |
| EPS reported | SGD | -1.84 | -1.00 | ||||||
| Operating cashflow per share | SGD | -3.57 | -3.57 | ||||||
| Capex per share | SGD | 0.02 | 0.02 | ||||||
| FCF per share | SGD | -3.59 | -3.59 | ||||||
| Free cash flow | SGD m | -9 | -4 | ||||||
| Net debt | SGD m | -3 | -3 | ||||||
| Book value equity | SGD m | 5 | 5 | ||||||
| Book value per share | SGD | 1.98 | 1.89 | ||||||
| Number of shares | m | 2.56 | 2.68 | ||||||
| DPS (TTM paid) | SGD | 0.00 | 0.00 |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.08 | 2.08 | ||||||
| P/S LTM | x | 211.01 | 392.99 | ||||||
| P/FCF LTM | x | -1.15 | -2.78 | ||||||
| EV/EBITDA LTM | x | -1.73 | -2.81 | ||||||
| EV/Sales LTM | x | 158.20 | 162.28 | ||||||
| Earnings Yield LTM | % | -44.39% | -45.63% | ||||||
| FCF Yield | % | -87.31% | -35.94% | ||||||
| Quality | |||||||||
| ROE | % | -92.44% | -1569.1% | ||||||
| ROIC | % | -82.48% | -82.48% | ||||||
| Operating margin | % | -91.55% | -91.55% | ||||||
| Gross margin | % | -1.29% | -1.29% | ||||||
| FCF/Sales | % | -18423.4% | -18423.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +3.26% | -44.56% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -19.04 | -7.84 | ||||||
| Net Debt/EBITDA | x | 0.58 | 0.58 | ||||||
| EBIT/Net interest | x | -310.21 | -310.21 | ||||||
| Net debt/market cap | % | +1.57% | +1.54% | ||||||
| Net debt/Equity | x | -0.58 | -0.58 | ||||||
| Gross debt/equity | x | 0.10 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free